A Phase 1, Open-label, Dose Escalation Study Of Pf-04518600 As A Single Agent And In Combination With Pf-05082566 In Patients With Selected Locally Advanced Or Metastatic Cancers

Trial Profile

A Phase 1, Open-label, Dose Escalation Study Of Pf-04518600 As A Single Agent And In Combination With Pf-05082566 In Patients With Selected Locally Advanced Or Metastatic Cancers

Recruiting
Phase of Trial: Phase I

Latest Information Update: 26 Nov 2017

At a glance

  • Drugs PF 4518600 (Primary) ; Utomilumab
  • Indications Head and neck cancer; Liver cancer; Malignant melanoma; Renal cell carcinoma
  • Focus Adverse reactions; First in man
  • Sponsors Pfizer
  • Most Recent Events

    • 03 Nov 2017 Planned End Date changed from 1 Aug 2020 to 21 Jul 2020.
    • 03 Nov 2017 Planned primary completion date changed from 1 Dec 2018 to 25 Nov 2018.
    • 12 Sep 2017 Results presented at the 42nd European Society for Medical Oncology Congress.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top